Fulgent Genetics To Acquire Inform Diagnostics, Lifts Q3 Revenue Outlook, Shares Up 5%

Shares of Fulgent Genetics, Inc. (FLGT) gained nearly 5% in extended trading session on Monday after the company announced the acquisition of Inform Diagnostics and lifted its revenue outlook.

Fulgent Genetics agreed to buy Inform Diagnostics, a national independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners, for a total price of about $170 million to be paid from cash on hand.

The acquisition is expected to close during the second quarter of 2022, subject to the satisfaction of customary closing conditions, including regulatory approvals.

Looking forward to the first quarter of 2022, Fulgent now anticipates revenue to be about $300 million, up from prior guidance of $245 million, and core revenue excluding COVID-19 NGS testing to be at least $22 million, consistent with previous guidance.

Analysts polled by Thomson Reuters currently estimate revenues of $244.65 million for the quarter.

FLGT closed Monday's trading at $55.26, down $0.87 or 1.55%, on the Nasdaq. The stock, however, gained $2.49 or 4.51%, in the after-hours trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
German sportswear company Adidas AG said Wednesday it will withdraw its request to block the application by the Black Lives Matter movement to trademark a yellow three-stripe design similar to Adidas' branding. This move by Adidas comes just 48 hours after it had filed an objection to the U.S. Patent and Trademark Office against the use of the three parallel stripes design. Generative artificial intelligence or AI technologies, including the highly popular ChatGPT, could expose around 300 million full-time jobs around the world to automation, a report by Goldman Sachs predicts, deepening the rising fears about job security. According to a new research report by GS economists, "The Potentially Large Effects of Artificial Intelligence on Economic Growth",.. UBS Group AG has called back its former Chief Executive Officer Sergio Ermotti to lead the Swiss banking giant amid the new challenges and priorities it faces following its planned acquisition of troubled domestic rival Credit Suisse Group AG. Following the news, UBS shares were gaining more than 2 percent in Swiss trading as well as in pre-market activity on the NYSE.
Follow RTT